Data / Drug companies / St. Mary's Medical Park Pharmacy
St. Mary's Medical Park Pharmacy: 280 products in the FDA NDC directory, labeler code 60760
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
St. Mary's Medical Park Pharmacy (labeler code 60760) lists 280 products in the FDA National Drug Code Directory, covering 126 finished drugs by generic name. By type: 278 prescription drugs, 2 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on November 2, 2026.
The request: Watch St. Mary's Medical Park Pharmacy (FDA labeler code 60760): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 60760
- Products in commercial distribution
- 280
- Packages
- 479
- Finished drugs by generic name
- 126
- Prescription products
- 278
- Over the counter products
- 2
- Controlled substance products
- Schedule II 19, Schedule III 3, Schedule IV 13, Schedule V 11
- Started marketing in the last 12 months
- 36
- Products with a marketing end date set
- 6
- Earliest marketing start
- July 26, 2000
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 275 | 98.2% |
| Authorized generics (NDA) | 3 | 1.1% |
| New drug applications (NDA) | 2 | 0.7% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 278 | 99.3% |
| Over the counter drugs | 2 | 0.7% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 116 | 41.4% |
| Tablet, film coated | 67 | 23.9% |
| Capsule | 47 | 16.8% |
| Tablet, extended release | 10 | 3.6% |
| Capsule, delayed release | 8 | 2.9% |
| Tablet, delayed release | 7 | 2.5% |
| Tablet, coated | 5 | 1.8% |
| Tablet, film coated, extended release | 5 | 1.8% |
| Capsule, extended release | 3 | 1.1% |
| Tablet, orally disintegrating | 3 | 1.1% |
| Ointment | 2 | 0.7% |
| Patch | 2 | 0.7% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Losartan potassium | 60760-876 | Tablet, film coated | Generic drugs (ANDA) | November 2, 2026 |
| Amitriptyline Hydrochloride | 60760-896 | Tablet | Generic drugs (ANDA) | October 29, 2026 |
| Hydrochlorothiazide | 60760-499 | Tablet | Generic drugs (ANDA) | October 27, 2026 |
| Atorvastatin calcium | 60760-979 | Tablet, film coated | Generic drugs (ANDA) | October 20, 2026 |
| Nitrofurantoin (monohydrate/macrocrystals) | 60760-848 | Capsule | Generic drugs (ANDA) | October 19, 2026 |
| Trazodone Hydrochloride | 60760-946 | Tablet | Generic drugs (ANDA) | October 14, 2026 |
| Gabapentin | 60760-943 | Tablet | Generic drugs (ANDA) | October 14, 2026 |
| Meclizine hydrochloride | 60760-997 | Tablet | Generic drugs (ANDA) | October 6, 2026 |
| Topiramate | 60760-952 | Tablet, film coated | Generic drugs (ANDA) | September 17, 2026 |
| Esomeprazole Magnesium | 60760-877 | Capsule, delayed release | Generic drugs (ANDA) | September 17, 2026 |
| Methocarbamol | 60760-874 | Tablet, film coated | Generic drugs (ANDA) | September 17, 2026 |
| Ciprofloxacin Hydrochloride | 60760-847 | Tablet, film coated | Generic drugs (ANDA) | September 17, 2026 |
| Naproxen | 60760-190 | Tablet | Generic drugs (ANDA) | September 16, 2026 |
| Metoprolol tartrate | 60760-944 | Tablet | Generic drugs (ANDA) | September 11, 2026 |
| Celecoxib | 60760-942 | Capsule | Generic drugs (ANDA) | August 25, 2026 |
| Atenolol | 60760-925 | Tablet | Generic drugs (ANDA) | August 25, 2026 |
| Valacyclovir | 60760-856 | Tablet | Generic drugs (ANDA) | August 12, 2026 |
| Oxycodone Hydrochloride | 60760-967 | Tablet | Generic drugs (ANDA) | August 6, 2026 |
| Morphine sulfate | 60760-893 | Tablet | Generic drugs (ANDA) | July 30, 2026 |
| Oxycodone Hydrochloride | 60760-966 | Tablet | Generic drugs (ANDA) | July 24, 2026 |
| Celecoxib | 60760-958 | Capsule | Generic drugs (ANDA) | July 24, 2026 |
| Ondansetron Hydrochloride | 60760-878 | Tablet, film coated | Generic drugs (ANDA) | July 24, 2026 |
| Gabapentin | 60760-940 | Capsule | Generic drugs (ANDA) | July 20, 2026 |
| Lorazepam | 60760-948 | Tablet | Generic drugs (ANDA) | July 7, 2026 |
| Lorazepam | 60760-947 | Tablet | Generic drugs (ANDA) | July 7, 2026 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.